May 05, 2025 8:00am EDT Can-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
Apr 17, 2025 8:55am EDT Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite’s Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
Apr 14, 2025 2:28pm EDT Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
Apr 14, 2025 8:30am EDT Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
Mar 24, 2025 9:00am EDT Can-Fite Initiates Pivotal Phase 3 Psoriasis Study of its Oral Drug Piclidenoson with FDA & EMA-Approved Protocol
Mar 20, 2025 9:45am EDT Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
Mar 19, 2025 9:00am EDT Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
Mar 18, 2025 8:30am EDT Can-Fite: FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient
Mar 03, 2025 6:00am EST Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
